PT-141 Research Guide: Bremelanotide Melanocortin Mechanism
PT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist studied for centrally-mediated sexual-response pathways — distinct from PDE5 inhibitors.
What is PT-141?
PT-141, generic name Bremelanotide, is a synthetic cyclic heptapeptide derived from Melanotan-II (MT-2). Both peptides are analogs of alpha-melanocyte-stimulating hormone (alpha-MSH).
Unlike MT-2, which produces pigmentation through MC1R, PT-141 is studied primarily for its effects at MC3R and MC4R. A separate, prescription bremelanotide product (Vyleesi) is approved in the United States for hypoactive sexual desire disorder; the research material listed here is not that product and is not approved for any human use.
Mechanism of action
PT-141 is a non-selective melanocortin agonist with primary activity at MC3R and MC4R. Its sexual-response effects appear to be mediated through MC4R activation in the medial preoptic area of the hypothalamus.
This central mechanism distinguishes PT-141 from PDE5 inhibitors (sildenafil, tadalafil), which act peripherally on vascular smooth muscle. PT-141's effects therefore do not depend on direct vascular response and can occur in subjects who do not respond to PDE5 inhibition.
Compliance reminder
PT-141 is sold for laboratory research use only. Not for human consumption, diagnosis, treatment, or cure of any disease.
Frequently asked questions
What is PT-141?
PT-141, generic name Bremelanotide, is a synthetic cyclic heptapeptide analog of alpha-MSH. It is a non-selective agonist at melanocortin receptors, with primary activity at MC3R and MC4R.
Mechanism?
Unlike PDE5 inhibitors which act on vascular smooth muscle, PT-141 acts centrally — primarily at MC4R in the hypothalamus — to modulate sexual-response pathways. A separate, prescription bremelanotide product (Vyleesi) is approved in the United States; the research material listed here is not that product and is not approved for any human use.